Skip to main content
Premium Trial:

Request an Annual Quote

Signature Dx to Use Affymetrix Chips for Cancer Test Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix and Signature Diagnostics today announced that they have inked an agreement under which Signature Dx has gained a worldwide license to use Affymetrix's microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer tests.

Potsdam, Germany-based Signature Dx intends to launch two microarray-based IVD tests by the fourth quarter of this year for colorectal cancer, the firms said. Signature will first launch the tests in Europe and intends to seek US regulatory approval at an unspecified time in the future.

Signature has been developing the tests, called Detector C and Predictor C. Detector C is a non-invasive, blood-based early detection test that the firm said has shown 90 percent sensitivity and 88 percent specificity for all four stages of colorectal cancer. Predictor C is a tissue test that predicts disease progression in stage II and III colorectal cancer patients and has been shown to identify half of all stage II/III patients with a high risk of disease progression.

"Our novel Detector C blood screening product together with Affymetrix's gene expression array technology brings CRC screening to a new level of accuracy and sensitivity," André Rosenthal, CEO of Signature Diagnostics, said in a statement.

Financial terms of the agreement were not disclosed.

The deal is part of Affy's 'Powered by Affymetrix's partnering program.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.